Your browser doesn't support javascript.
loading
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit, R; Wülfing, C; Castellano, D; Kramer, G; Eymard, J-C; Sternberg, C N; Fizazi, K; Tombal, B; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdóttir, Á; Theodore, C; Feyerabend, S; Helissey, C; Foster, M C; Ozatilgan, A; Geffriaud-Ricouard, C; de Bono, J.
Afiliação
  • de Wit R; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: r.dewit@erasmusmc.nl.
  • Wülfing C; Department of Urology, Asklepios Tumorzentrum, Hamburg, Germany.
  • Castellano D; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
  • Kramer G; Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Eymard JC; Department of Medical Oncology, Institute Jean Godinot, Reims, France.
  • Sternberg CN; Division of Hematology and Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA.
  • Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; University of Paris Saclay, Saint-Aubin, France.
  • Tombal B; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium.
  • Bamias A; Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Carles J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Iacovelli R; Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; Department of Medical Oncology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
  • Melichar B; Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
  • Sverrisdóttir Á; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland.
  • Theodore C; Department of Oncology, Foch Hospital, Suresnes, France.
  • Feyerabend S; Studienpraxis Urologie, Nürtingen, Germany.
  • Helissey C; Hôpital d'Instruction des Armées Bégin, Saint Mandé, France.
  • Foster MC; Global Medical Oncology, Sanofi, Cambridge, USA.
  • Ozatilgan A; Global Medical Oncology, Sanofi, Cambridge, USA.
  • Geffriaud-Ricouard C; Europe Medical Oncology, Sanofi, Paris, France.
  • de Bono J; Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Targeted Therapy Group, Royal Marsden Hospital, London, UK.
ESMO Open ; 6(5): 100241, 2021 10.
Article em En | MEDLINE | ID: mdl-34450475
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article